EntreMed Presents Mechanism Data for Its Three Lead Oncology Compounds - Drug Newswire (press release)
March 29, 2007| EntreMed Presents Mechanism Data for Its Three Lead Oncology Compounds Drug Newswire (press release), CT - ... cell cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. ... |
OTN's Specialty Pharmacy, ivpcare, Selected to Dispense Newly ... - Drug Newswire (press release)
March 29, 2007| OTN's Specialty Pharmacy, ivpcare, Selected to Dispense Newly ... Drug Newswire (press release), CT - The US Food and Drug Administration approved Tykerb on March 13, 2007, for the treatment of advanced or metastatic breast cancer in combination with ... Oklahoma Oncology Selects OTN and Onmark as Oncology Services Partner |
Nitec Pharma AG Closes CHF 32 Million (approx. US$ 26 million ... - PR Newswire (press release)
March 29, 2007| Nitec Pharma AG Closes CHF 32 Million (approx. US$ 26 million ... PR Newswire (press release), NY - The proceeds will be used to develop further Nitec's lead product Lodotra(TM) in Rheumatoid Arthritis (RA) and other indications and to develop a second ... |
4SC AG Reports on Successful Financial Year 2006 - PR Newswire UK (press release)
March 29, 2007| 4SC AG Reports on Successful Financial Year 2006 PR Newswire UK (press release), UK - For the most advanced of the six pipeline projects with the drug candidate SC12267 for the treatment of rheumatoid arthritis, a clinical phase IIa study ... |